February 22, 2013 — Digirad Corporation announced the launch of their Molecular Breast Imaging Accessory for the ergo imaging system, further expanding the clinical flexibility of the ergo imaging system for applications in the area of women’s health, as well as in nuclear medicine where the ergo imaging system is currently used for a wide variety of clinical applications.
The introduction of Digirad’s Molecular Breast Imaging Accessory follows the U.S. Food and Drug Administration (FDA) 510(k) market clearance recently received for expanded use of the ergo Imaging System, which includes indications for use to aid in the evaluation of lesions in the breast and other small body parts. When used for breast imaging, the ergo Imaging System can be used as an adjunct to mammography or other primary breast imaging modalities.
Digirad Chief Executive Officer Todd Clyde noted that this launch marks another key step in the company’s strategy to expand its imaging technology footprint in the hospital through the use of flexible, portable systems with devices that have expanded diagnostics capabilities.
“We believe the Molecular Breast Imaging Accessory fills an important market need and is a natural addition to the ergo imaging system,” said Clyde. “Advanced diagnostic modalities are often necessary to help clinicians identify lesions in the breast, and our new Molecular Breast Imaging Accessory provides this capability. It is a cost-effective, non-dedicated option for molecular breast imaging that enhances the clinical capabilities and operational efficiencies of the ergo imaging system.”
Annual mammograms are recommended by the American Cancer Society for women age 40 and older, however, not all breast cancers can be detected by mammography, especially in dense breasts. Accordingly, adjunctive diagnostics such as molecular breast imaging can help physicians spot lesions in dense and complex breast tissue.
The user-friendly design of the ergo Molecular Breast Imaging Accessory includes a specialized breast imaging assembly and breast-mode software to capture all normal mammographic views for direct correlation with the patient’s mammogram. Additionally, it uses Digirad’s industry-leading solid-state detector technology with an oversized field-of-view to obtain comprehensive, high-contrast images. The open design provides easy access for hands-free breast positioning on patients who can be seated, standing or lying down during the examination.
For more information: www.digirad.com
July 30, 2024 
